Stoic VC

Stoic VC operates from Sydney with a structural specialization that defines its entire approach: it co-invests exclusively in deep tech and life science spin-outs originating from Australian universities. Investment activity spans biotech, medical devices, and deep tech, with the firm positioned to back the formation rounds of academic spin-outs alongside university commercialization offices and other early backers. The model is tightly coupled to the Australian university ecosystem, which gives Stoic VC unusual visibility into early IP and an ability to engage with companies before they appear in standard venture pipelines. Limited public information is available about individual partners and a fully disclosed portfolio in mainstream sources, so founders should plan to confirm specifics in direct conversation.

Check sizes are typically in the two hundred fifty thousand to one million dollar range, deployed at seed and Series A. Geographic focus is firmly Australia, with companies expected to have university spin-out origins as a baseline qualifier. The relatively small check size positions Stoic VC as a co-investor and ecosystem partner rather than a lead in larger institutional rounds, but the firm’s specialization gives it a meaningful role in shaping early cap tables.

For founders coming out of an Australian university with deep tech or life science IP, Stoic VC is one of the more natural conversations available. Expect a partner that understands tech transfer mechanics, IP assignment, and the operating realities of taking research out of an academic environment. Founders without a university spin-out origin will not fit the mandate. Those who do benefit from an investor purpose-built to bridge the gap between academic invention and a financeable company.